INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Contingent Liabilities History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | - | ₹0.98 Cr | ₹0.95 Cr | ₹0.67 Cr | ₹0.59 Cr |
What is the latest Contingent Liabilities ratio of INDO US BIOTECH ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | - |
| Mar2024 | ₹0.98 Cr |
| Mar2023 | ₹0.95 Cr |
| Mar2022 | ₹0.67 Cr |
| Mar2021 | ₹0.59 Cr |
How is Contingent Liabilities of INDO US BIOTECH Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | - | -100.00 | |
| Mar2024 | ₹0.98 Cr | 2.84 | |
| Mar2023 | ₹0.95 Cr | 42.64 | |
| Mar2022 | ₹0.67 Cr | 13.27 | |
| Mar2021 | ₹0.59 Cr | - | |
Compare Contingent Liabilities of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹199.3 Cr | -3.1% | -24.8% | -46.6% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹10,634.6 Cr | -0.8% | -17.7% | -12.5% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹4,168.6 Cr | 5.6% | -9.3% | -24.5% | Stock Analytics | |
| VENKYS (INDIA) | ₹1,709.7 Cr | -4.1% | -15.9% | -24.1% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹861.0 Cr | -1.6% | -10.7% | -38.2% | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹336.5 Cr | 2.6% | -18.9% | -36.2% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | -3.1% |
-24.8% |
-46.6% |
| SENSEX | -5.5% |
-11.5% |
0.3% |
You may also like the below Video Courses